Education
About Us
Working with TipRanks
Follow Us
Tenax Therapeutics (TENX)
NASDAQ:TENX
Total Valuation
Tenax Therapeutics has a market cap or net worth of $238.01M. The enterprise value is -$34.42M.
Market Cap$238.01M
Enterprise Value-$34.42M
Share Statistics
Tenax Therapeutics has 17,197,613 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding17,197,613
Owned by Insiders0.51%
Owned by Institutions63.12%
Financial Efficiency
Tenax Therapeutics’s return on equity (ROE) is -0.54 and return on invested capital (ROIC) is -58.09%.
Return on Equity (ROE)-0.54
Return on Assets (ROA)-0.50
Return on Invested Capital (ROIC)-58.09%
Return on Capital Employed (ROCE)-0.58
Revenue Per Employee0.00
Profits Per Employee-13.15M
Employee Count4
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tenax Therapeutics is ―. Tenax Therapeutics’s PEG ratio is -0.55.
PE Ratio―
PS Ratio0.00
PB Ratio4.92
Price to Fair Value4.92
Price to FCF-13.35
Price to Operating Cash Flow-15.16
PEG Ratio-0.55
Income Statement
In the last 12 months, Tenax Therapeutics had revenue of 0.00 and earned -52.60M in profits. Earnings per share was -1.34.
Revenue0.00
Gross Profit0.00
Operating Income-56.38M
Pretax Income-52.60M
Net Income-52.60M
EBITDA-56.38M
Earnings Per Share (EPS)-1.34
Cash Flow
In the last 12 months, operating cash flow was -35.80M and capital expenditures 0.00, giving a free cash flow of -35.80M billion.
Operating Cash Flow-35.80M
Free Cash Flow-35.80M
Free Cash Flow per Share-2.08
Dividends & Yields
Tenax Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change122.15%
50-Day Moving Average13.24
200-Day Moving Average8.66
Relative Strength Index (RSI)57.36
Average Volume (3m)287.49K
Important Dates
Tenax Therapeutics upcoming earnings date is May 19, 2026, TBA (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Tenax Therapeutics as a current ratio of 14.56, with Debt / Equity ratio of 0.00%
Current Ratio14.56
Quick Ratio14.56
Debt to Market Cap0.00
Net Debt to EBITDA1.73
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tenax Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tenax Therapeutics EV to EBITDA ratio is -6.75, with an EV/FCF ratio of -10.63.
EV to Sales0.00
EV to EBITDA-6.75
EV to Free Cash Flow-10.63
EV to Operating Cash Flow-10.63
Balance Sheet
Tenax Therapeutics has $97.56M in cash and marketable securities with $0.00 in debt, giving a net cash position of $97.56M billion.
Cash & Marketable Securities$97.56M
Total Debt$0.00
Net Cash$97.56M
Net Cash Per Share$5.67
Tangible Book Value Per Share$2.48
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tenax Therapeutics is $30.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.33
Price Target Upside119.15% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast92.89%